6.
Freedman B, Martinez C, Katholing A, Rietbrock S
. Residual Risk of Stroke and Death in Anticoagulant-Treated Patients With Atrial Fibrillation. JAMA Cardiol. 2016; 1(3):366-8.
DOI: 10.1001/jamacardio.2016.0393.
View
7.
Santhanakrishnan R, Wang N, Larson M, Magnani J, McManus D, Lubitz S
. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016; 133(5):484-92.
PMC: 4738087.
DOI: 10.1161/CIRCULATIONAHA.115.018614.
View
8.
Shah A, Mittal S, Sichrovsky T, Cotiga D, Arshad A, Maleki K
. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol. 2008; 19(7):661-7.
DOI: 10.1111/j.1540-8167.2008.01101.x.
View
9.
McKenna C, Palmer S, Rodgers M, Chambers D, Hawkins N, Golder S
. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart. 2008; 95(7):542-9.
DOI: 10.1136/hrt.2008.147165.
View
10.
Andrade J
. Ablation as First-line Therapy for Atrial Fibrillation. Eur Cardiol. 2023; 18:e46.
PMC: 10398511.
DOI: 10.15420/ecr.2023.04.
View
11.
Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu M, Rasmussen L
. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2014; 128(5):509-18.e2.
DOI: 10.1016/j.amjmed.2014.11.026.
View
12.
Zafrir B, Lund L, Laroche C, Ruschitzka F, Crespo-Leiro M, Coats A
. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39(48):4277-4284.
DOI: 10.1093/eurheartj/ehy626.
View
13.
Maesen B, van der Heijden C, Bidar E, Vos R, Athanasiou T, Maessen J
. Patient-reported quality of life after stand-alone and concomitant arrhythmia surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2021; 34(3):339-348.
PMC: 8860412.
DOI: 10.1093/icvts/ivab282.
View
14.
Raymond R, Lee A, Messineo F, Manning W, Silverman D
. Cardiac performance early after cardioversion from atrial fibrillation. Am Heart J. 1998; 136(3):435-42.
DOI: 10.1016/s0002-8703(98)70217-0.
View
15.
Morillo C, Verma A, Connolly S, Kuck K, Nair G, Champagne J
. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014; 311(7):692-700.
DOI: 10.1001/jama.2014.467.
View
16.
Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R
. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008; 118(24):2498-505.
DOI: 10.1161/CIRCULATIONAHA.108.772582.
View
17.
Inada K, Yamane T, Tokutake K, Yokoyama K, Mishima T, Hioki M
. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up. Europace. 2013; 16(2):208-13.
DOI: 10.1093/europace/eut159.
View
18.
Takigawa M, Takahashi A, Kuwahara T, Takahashi Y, Okubo K, Nakashima E
. Impact of Alcohol Consumption on the Outcome of Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation. J Am Heart Assoc. 2016; 5(12).
PMC: 5210418.
DOI: 10.1161/JAHA.116.004149.
View
19.
Turagam M, Musikantow D, Whang W, Koruth J, Miller M, Langan M
. Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials. JAMA Cardiol. 2021; 6(6):697-705.
PMC: 8082432.
DOI: 10.1001/jamacardio.2021.0852.
View
20.
Roy D, Talajic M, Dorian P, Connolly S, Eisenberg M, Green M
. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000; 342(13):913-20.
DOI: 10.1056/NEJM200003303421302.
View